Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17465
Country/Region: Eswatini
Year: 2018
Main Partner: John Snow, Inc
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USAID
Total Funding: $4,577,351 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,216,950
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $425,934
Care: Pediatric Care and Support (PDCS) $160,812
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,047,444
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $231,098
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,277,799
Treatment: Pediatric Treatment (PDTX) $217,314
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 21
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 40
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 6
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 59
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 35
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 5
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 63
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 57
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 11
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 98
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 15
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 91
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 16
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 40
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 97
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 15
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 38
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 16
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 501
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 88
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 246
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 58
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 30
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 86
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 21
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 50
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 41
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 69
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 12
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 57
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 23
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 69
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 12
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 69
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 23
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 621
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 98
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 1,266
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 202
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 654
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 101
GEND_GBV Number of people receiving post-GBV care 2019 1,920
GEND_GBV Number of people receiving post-GBV care 2019 303
HTS_SELF 10-14, Female, Directly-Assisted 2019 7
HTS_SELF 10-14, Female, Directly-Assisted 2019 165
HTS_SELF 10-14, Female, Unassisted 2019 16
HTS_SELF 10-14, Female, Unassisted 2019 332
HTS_SELF 10-14, Male, Directly-Assisted 2019 7
HTS_SELF 10-14, Male, Directly-Assisted 2019 165
HTS_SELF 10-14, Male, Unassisted 2019 7
HTS_SELF 10-14, Male, Unassisted 2019 165
HTS_SELF 15-19, Female, Directly-Assisted 2019 165
HTS_SELF 15-19, Female, Directly-Assisted 2019 7
HTS_SELF 15-19, Female, Unassisted 2019 165
HTS_SELF 15-19, Female, Unassisted 2019 7
HTS_SELF 15-19, Male, Directly-Assisted 2019 499
HTS_SELF 15-19, Male, Directly-Assisted 2019 24
HTS_SELF 15-19, Male, Unassisted 2019 828
HTS_SELF 15-19, Male, Unassisted 2019 44
HTS_SELF 20-24, Female, Directly-Assisted 2019 499
HTS_SELF 20-24, Female, Directly-Assisted 2019 24
HTS_SELF 20-24, Female, Unassisted 2019 828
HTS_SELF 20-24, Female, Unassisted 2019 44
HTS_SELF 20-24, Male, Directly-Assisted 2019 499
HTS_SELF 20-24, Male, Directly-Assisted 2019 24
HTS_SELF 20-24, Male, Unassisted 2019 828
HTS_SELF 20-24, Male, Unassisted 2019 45
HTS_SELF 25-29, Female, Directly-Assisted 2019 499
HTS_SELF 25-29, Female, Directly-Assisted 2019 24
HTS_SELF 25-29, Female, Unassisted 2019 828
HTS_SELF 25-29, Female, Unassisted 2019 45
HTS_SELF 25-29, Male, Directly-Assisted 2019 499
HTS_SELF 25-29, Male, Directly-Assisted 2019 24
HTS_SELF 25-29, Male, Unassisted 2019 828
HTS_SELF 25-29, Male, Unassisted 2019 45
HTS_SELF 30-34, Female, Directly-Assisted 2019 499
HTS_SELF 30-34, Female, Directly-Assisted 2019 24
HTS_SELF 30-34, Female, Unassisted 2019 828
HTS_SELF 30-34, Female, Unassisted 2019 45
HTS_SELF 30-34, Male, Directly-Assisted 2019 499
HTS_SELF 30-34, Male, Directly-Assisted 2019 24
HTS_SELF 30-34, Male, Unassisted 2019 829
HTS_SELF 30-34, Male, Unassisted 2019 45
HTS_SELF 35-39, Female, Directly-Assisted 2019 499
HTS_SELF 35-39, Female, Directly-Assisted 2019 24
HTS_SELF 35-39, Female, Unassisted 2019 829
HTS_SELF 35-39, Female, Unassisted 2019 45
HTS_SELF 35-39, Male, Directly-Assisted 2019 499
HTS_SELF 35-39, Male, Directly-Assisted 2019 24
HTS_SELF 35-39, Male, Unassisted 2019 828
HTS_SELF 35-39, Male, Unassisted 2019 45
HTS_SELF 40-49, Female, Directly-Assisted 2019 499
HTS_SELF 40-49, Female, Directly-Assisted 2019 24
HTS_SELF 40-49, Female, Unassisted 2019 828
HTS_SELF 40-49, Female, Unassisted 2019 45
HTS_SELF 40-49, Male, Directly-Assisted 2019 499
HTS_SELF 40-49, Male, Directly-Assisted 2019 24
HTS_SELF 40-49, Male, Unassisted 2019 1,692
HTS_SELF 40-49, Male, Unassisted 2019 117
HTS_SELF Unassisted - Other 2019 3,509
HTS_SELF Unassisted - Other 2019 197
HTS_SELF Unassisted - Self 2019 3,618
HTS_SELF Unassisted - Self 2019 201
HTS_SELF Unassisted - Sex Partner 2019 3,509
HTS_SELF Unassisted - Sex Partner 2019 197
HTS_TST 25-29, Female, Negative 2019 50
HTS_TST 25-29, Female, Negative 2019 11
HTS_TST 25-29, Female, Negative 2019 247
HTS_TST 25-29, Female, Negative 2019 42
HTS_TST 25-29, Female, Negative 2019 1,976
HTS_TST 25-29, Female, Negative 2019 1,098
HTS_TST 25-29, Female, Negative 2019 10
HTS_TST 25-29, Female, Negative 2019 239
HTS_TST 25-29, Female, Negative 2019 10
HTS_TST 25-29, Female, Negative 2019 82
HTS_TST 25-29, Male, Negative 2019 14
HTS_TST 25-29, Male, Negative 2019 301
HTS_TST 25-29, Male, Negative 2019 51
HTS_TST 25-29, Male, Negative 2019 2,588
HTS_TST 25-29, Male, Negative 2019 78
HTS_TST 25-29, Male, Negative 2019 300
HTS_TST 25-29, Male, Negative 2019 12
HTS_TST 25-29, Male, Negative 2019 108
HTS_TST 30-34, Female, Negative 2019 50
HTS_TST 30-34, Female, Negative 2019 15
HTS_TST 30-34, Female, Negative 2019 162
HTS_TST 30-34, Female, Negative 2019 28
HTS_TST 30-34, Female, Negative 2019 1,412
HTS_TST 30-34, Female, Negative 2019 1,098
HTS_TST 30-34, Female, Negative 2019 10
HTS_TST 30-34, Female, Negative 2019 166
HTS_TST 30-34, Female, Negative 2019 6
HTS_TST 30-34, Female, Negative 2019 58
HTS_TST 30-34, Male, Negative 2019 8
HTS_TST 30-34, Male, Negative 2019 319
HTS_TST 30-34, Male, Negative 2019 51
HTS_TST 30-34, Male, Negative 2019 2,415
HTS_TST 30-34, Male, Negative 2019 86
HTS_TST 30-34, Male, Negative 2019 314
HTS_TST 30-34, Male, Negative 2019 12
HTS_TST 30-34, Male, Negative 2019 100
HTS_TST 35-39, Female, Negative 2019 40
HTS_TST 35-39, Female, Negative 2019 7
HTS_TST 35-39, Female, Negative 2019 162
HTS_TST 35-39, Female, Negative 2019 24
HTS_TST 35-39, Female, Negative 2019 1,319
HTS_TST 35-39, Female, Negative 2019 831
HTS_TST 35-39, Female, Negative 2019 10
HTS_TST 35-39, Female, Negative 2019 148
HTS_TST 35-39, Female, Negative 2019 6
HTS_TST 35-39, Female, Negative 2019 56
HTS_TST 35-39, Male, Negative 2019 2
HTS_TST 35-39, Male, Negative 2019 297
HTS_TST 35-39, Male, Negative 2019 46
HTS_TST 35-39, Male, Negative 2019 2,354
HTS_TST 35-39, Male, Negative 2019 65
HTS_TST 35-39, Male, Negative 2019 282
HTS_TST 35-39, Male, Negative 2019 16
HTS_TST 35-39, Male, Negative 2019 98
HTS_TST 40-49, Female, Negative 2019 8
HTS_TST 40-49, Female, Negative 2019 137
HTS_TST 40-49, Female, Negative 2019 24
HTS_TST 40-49, Female, Negative 2019 1,179
HTS_TST 40-49, Female, Negative 2019 207
HTS_TST 40-49, Female, Negative 2019 10
HTS_TST 40-49, Female, Negative 2019 141
HTS_TST 40-49, Female, Negative 2019 6
HTS_TST 40-49, Female, Negative 2019 50
HTS_TST 40-49, Male, Negative 2019 319
HTS_TST 40-49, Male, Negative 2019 51
HTS_TST 40-49, Male, Negative 2019 1,102
HTS_TST 40-49, Male, Negative 2019 65
HTS_TST 40-49, Male, Negative 2019 311
HTS_TST 40-49, Male, Negative 2019 12
HTS_TST 40-49, Male, Negative 2019 46
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 79,282
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 3,146
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 890
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 39
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 1,090
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 51
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 5
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 577
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 6
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 235
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 227
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 137
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 82
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 300
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 12
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 189
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 8
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 162
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 8
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 11
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 627
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 250
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 251
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 24
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 14
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 51
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 33
HTS_TST Service Delivery Point (Facility) Other PITC: <1, Negative 2019 7
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 7,671
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 445
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 5,599
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 292
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 5,590
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 308
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 1,096
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 49
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 657
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 30
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 2,408
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 108
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 1,534
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 64
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 22,717
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 649
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 3
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 2
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 15
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 44
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 5
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 7
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 4
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 6
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 237
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 14
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 94
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 4
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 95
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 5
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 140
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 3
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 78
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 6
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 301
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 12
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 191
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 9
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 169
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 138
HTS_TST_POS 25-29, Female, Positive 2019 6
HTS_TST_POS 25-29, Female, Positive 2019 40
HTS_TST_POS 25-29, Female, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 60
HTS_TST_POS 25-29, Female, Positive 2019 149
HTS_TST_POS 25-29, Female, Positive 2019 8
HTS_TST_POS 25-29, Female, Positive 2019 19
HTS_TST_POS 25-29, Female, Positive 2019 2
HTS_TST_POS 25-29, Female, Positive 2019 2
HTS_TST_POS 25-29, Male, Positive 2019 50
HTS_TST_POS 25-29, Male, Positive 2019 5
HTS_TST_POS 25-29, Male, Positive 2019 73
HTS_TST_POS 25-29, Male, Positive 2019 67
HTS_TST_POS 25-29, Male, Positive 2019 19
HTS_TST_POS 25-29, Male, Positive 2019 2
HTS_TST_POS 25-29, Male, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 6
HTS_TST_POS 30-34, Female, Positive 2019 20
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Female, Positive 2019 40
HTS_TST_POS 30-34, Female, Positive 2019 149
HTS_TST_POS 30-34, Female, Positive 2019 8
HTS_TST_POS 30-34, Female, Positive 2019 16
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 45
HTS_TST_POS 30-34, Male, Positive 2019 5
HTS_TST_POS 30-34, Male, Positive 2019 73
HTS_TST_POS 30-34, Male, Positive 2019 70
HTS_TST_POS 30-34, Male, Positive 2019 19
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 4
HTS_TST_POS 35-39, Female, Positive 2019 6
HTS_TST_POS 35-39, Female, Positive 2019 22
HTS_TST_POS 35-39, Female, Positive 2019 2
HTS_TST_POS 35-39, Female, Positive 2019 33
HTS_TST_POS 35-39, Female, Positive 2019 107
HTS_TST_POS 35-39, Female, Positive 2019 8
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 2
HTS_TST_POS 35-39, Male, Positive 2019 45
HTS_TST_POS 35-39, Male, Positive 2019 5
HTS_TST_POS 35-39, Male, Positive 2019 70
HTS_TST_POS 35-39, Male, Positive 2019 39
HTS_TST_POS 35-39, Male, Positive 2019 18
HTS_TST_POS 35-39, Male, Positive 2019 2
HTS_TST_POS 35-39, Male, Positive 2019 4
HTS_TST_POS 40-49, Female, Positive 2019 22
HTS_TST_POS 40-49, Female, Positive 2019 2
HTS_TST_POS 40-49, Female, Positive 2019 33
HTS_TST_POS 40-49, Female, Positive 2019 19
HTS_TST_POS 40-49, Female, Positive 2019 8
HTS_TST_POS 40-49, Female, Positive 2019 3
HTS_TST_POS 40-49, Female, Positive 2019 2
HTS_TST_POS 40-49, Male, Positive 2019 50
HTS_TST_POS 40-49, Male, Positive 2019 5
HTS_TST_POS 40-49, Male, Positive 2019 73
HTS_TST_POS 40-49, Male, Positive 2019 39
HTS_TST_POS 40-49, Male, Positive 2019 19
HTS_TST_POS 40-49, Male, Positive 2019 2
HTS_TST_POS 40-49, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 120
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 141
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 47
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 32
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 252
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 107
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 105
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 78
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 50
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 479
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 27
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 3
PMTCT_ART Already on ART at beginning of current pregnancy 2019 1,132
PMTCT_ART Already on ART at beginning of current pregnancy 2019 81
PMTCT_ART New on ART 2019 1,304
PMTCT_ART New on ART 2019 85
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 2,436
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 166
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 7,698
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 516
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 1,951
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 134
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 495
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 32
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 2,446
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 166
PMTCT_EID Sum of Infant Age disaggregates 2019 2,446
PMTCT_EID Sum of Infant Age disaggregates 2019 166
PMTCT_STAT 25-29, Female 2019 2,287
PMTCT_STAT 25-29, Female 2019 156
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 548
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 37
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 1,537
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 107
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 202
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 12
PMTCT_STAT 30-34, Female 2019 1,446
PMTCT_STAT 30-34, Female 2019 135
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 281
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 17
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 1,033
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 106
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 132
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 12
PMTCT_STAT 35-39, Female 2019 884
PMTCT_STAT 35-39, Female 2019 39
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 188
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 11
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 616
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 28
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 80
PMTCT_STAT 40-49, Female 2019 135
PMTCT_STAT 40-49, Female 2019 9
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 10
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 118
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 9
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 7
PMTCT_STAT By Age (Numerator): : 15-19 2019 49
PMTCT_STAT By Age (Numerator): 10-14 2019 78
PMTCT_STAT By Age (Numerator): 15-19 2019 1,159
PMTCT_STAT By Age (Numerator): 20-24 2019 1,709
PMTCT_STAT By Age (Numerator): 20-24 2019 128
PMTCT_STAT By known positives: 15-19 2019 18
PMTCT_STAT By known positives: 20-24 2019 38
PMTCT_STAT By new negatives: 15-19 2019 28
PMTCT_STAT By new negatives: 20-24 2019 77
PMTCT_STAT By new positives: 15-19 2019 3
PMTCT_STAT By new positives: 20-24 2019 13
PMTCT_STAT By Number of known positives: 10-14 2019 9
PMTCT_STAT By Number of known positives: 15-19 2019 286
PMTCT_STAT By Number of known positives: 20-24 2019 548
PMTCT_STAT By Number of new negative: 10-14 2019 71
PMTCT_STAT By Number of new negative: 15-19 2019 769
PMTCT_STAT By Number of new negative: 20-24 2019 1,029
PMTCT_STAT By Number of new positives: 15-19 2019 104
PMTCT_STAT By Number of new positives: 20-24 2019 132
PMTCT_STAT Number of new ANC and L&D clients 2019 8,090
PMTCT_STAT Number of new ANC and L&D clients 2019 543
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 7,698
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 516
PMTCT_STAT_den 25-29, Female 2019 2,352
PMTCT_STAT_den 25-29, Female 2019 156
PMTCT_STAT_den 30-34, Female 2019 1,222
PMTCT_STAT_den 30-34, Female 2019 82
PMTCT_STAT_den 35-39, Female 2019 811
PMTCT_STAT_den 35-39, Female 2019 54
PMTCT_STAT_den 40-49, Female 2019 80
PMTCT_STAT_den 40-49, Female 2019 6
PMTCT_STAT_den By Age (Denominator): <15-19 2019 1,211
PMTCT_STAT_den By Age (Denominator): 10-14 2019 82
PMTCT_STAT_den By Age (Denominator): 10-14 2019 6
PMTCT_STAT_den By Age (Denominator): 15-19 2019 82
PMTCT_STAT_den By Age (Denominator): 20-24 2019 2,332
PMTCT_STAT_den By Age (Denominator): 20-24 2019 157
PrEP_NEW 25-29, Female 2019 64
PrEP_NEW 25-29, Male 2019 38
PrEP_NEW 30-34, Female 2019 58
PrEP_NEW 30-34, Male 2019 37
PrEP_NEW 35-39, Female 2019 64
PrEP_NEW 35-39, Male 2019 37
PrEP_NEW 40-49, Female 2019 58
PrEP_NEW 40-49, Male 2019 31
PrEP_NEW Female 15-19 2019 57
PrEP_NEW Female 20-24 2019 63
PrEP_NEW Male 15-19 2019 37
PrEP_NEW Male 20-24 2019 38
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 577
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 3
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 298
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 4
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 452
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 757
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 2
TB_PREV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 14,895
TB_PREV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 121
TB_PREV Alternative TPT Regimen, Life-long ART, New, Positive 2019 14,920
TB_PREV Alternative TPT Regimen, Life-long ART, New, Positive 2019 124
TB_PREV By Age/Sex (Numerator): <15, Female 2019 528
TB_PREV By Age/Sex (Numerator): <15, Female 2019 5
TB_PREV By Age/Sex (Numerator): <15, Male 2019 724
TB_PREV By Age/Sex (Numerator): <15, Male 2019 6
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 9,588
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 82
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 18,984
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 156
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 29,823
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 240
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 35,081
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 282
TB_PREV_den Alternative TPT Regimen, Life-long ART, Already, Positive 2019 17,536
TB_PREV_den Alternative TPT Regimen, Life-long ART, Already, Positive 2019 135
TB_PREV_den Alternative TPT Regimen, Life-long ART, New, Positive 2019 17,545
TB_PREV_den Alternative TPT Regimen, Life-long ART, New, Positive 2019 147
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 701
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 5
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 701
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 5
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 11,240
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 91
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 22,439
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 181
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 24
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 459
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 5
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 24
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 647
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 10
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 1,154
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 15
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 1,154
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 15
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 24
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 457
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 5
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 24
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 649
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 10
TX_CURR 25-29, Female, Positive 2019 7,443
TX_CURR 25-29, Female, Positive 2019 130
TX_CURR 25-29, Male, Positive 2019 2,084
TX_CURR 25-29, Male, Positive 2019 54
TX_CURR 30-34, Female, Positive 2019 7,961
TX_CURR 30-34, Female, Positive 2019 78
TX_CURR 30-34, Male, Positive 2019 4,614
TX_CURR 30-34, Male, Positive 2019 51
TX_CURR 35-39, Female, Positive 2019 7,020
TX_CURR 35-39, Female, Positive 2019 112
TX_CURR 35-39, Male, Positive 2019 5,577
TX_CURR 35-39, Male, Positive 2019 85
TX_CURR 40-49, Female, Positive 2019 8,896
TX_CURR 40-49, Female, Positive 2019 166
TX_CURR 40-49, Male, Positive 2019 7,162
TX_CURR 40-49, Male, Positive 2019 104
TX_CURR Age/Sex: <1 2019 129
TX_CURR Age/Sex: <1 2019 1
TX_CURR Age/Sex: <1-9 2019 2,173
TX_CURR Age/Sex: 1-9 2019 22
TX_CURR Age/Sex: 10-14 Female 2019 1,237
TX_CURR Age/Sex: 10-14 Female 2019 19
TX_CURR Age/Sex: 10-14 Male 2019 1,247
TX_CURR Age/Sex: 10-14 Male 2019 18
TX_CURR Age/Sex: 15-19 Female 2019 2,029
TX_CURR Age/Sex: 15-19 Female 2019 19
TX_CURR Age/Sex: 15-19 Male 2019 778
TX_CURR Age/Sex: 15-19 Male 2019 9
TX_CURR Age/Sex: 20-24 Female 2019 3,817
TX_CURR Age/Sex: 20-24 Female 2019 49
TX_CURR Age/Sex: 20-24 Male 2019 968
TX_CURR Age/Sex: 20-24 Male 2019 9
TX_CURR Age/Sex: 50+ Female 2019 6,116
TX_CURR Age/Sex: 50+ Female 2019 112
TX_CURR Age/Sex: 50+ Male 2019 6,081
TX_CURR Age/Sex: 50+ Male 2019 79
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 75,332
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 1,117
TX_CURR Sum of age/sex disaggregates 2019 2,807
TX_CURR Sum of Age/Sex disaggregations 2019 28
TX_NEW 25-29, Female, Positive 2019 366
TX_NEW 25-29, Female, Positive 2019 11
TX_NEW 25-29, Male, Positive 2019 455
TX_NEW 25-29, Male, Positive 2019 13
TX_NEW 30-34, Female, Positive 2019 273
TX_NEW 30-34, Female, Positive 2019 4
TX_NEW 30-34, Male, Positive 2019 540
TX_NEW 30-34, Male, Positive 2019 13
TX_NEW 35-39, Female, Positive 2019 369
TX_NEW 35-39, Female, Positive 2019 8
TX_NEW 35-39, Male, Positive 2019 588
TX_NEW 35-39, Male, Positive 2019 13
TX_NEW 40-49, Female, Positive 2019 318
TX_NEW 40-49, Female, Positive 2019 7
TX_NEW 40-49, Male, Positive 2019 591
TX_NEW 40-49, Male, Positive 2019 13
TX_NEW Breastfeeding status 2019 167
TX_NEW Breastfeeding status 2019 5
TX_NEW By Age/Sex: <1 2019 60
TX_NEW By Age/Sex: <1 2019 1
TX_NEW By Age/Sex: 1-9 2019 502
TX_NEW By Age/Sex: 1-9 2019 12
TX_NEW By Age/Sex: 10-14 Female 2019 261
TX_NEW By Age/Sex: 10-14 Female 2019 6
TX_NEW By Age/Sex: 10-14 Male 2019 251
TX_NEW By Age/Sex: 10-14 Male 2019 7
TX_NEW By Age/Sex: 15-19 Female 2019 131
TX_NEW By Age/Sex: 15-19 Female 2019 1
TX_NEW By Age/Sex: 15-19 Male 2019 87
TX_NEW By Age/Sex: 20-24 Female 2019 427
TX_NEW By Age/Sex: 20-24 Female 2019 33
TX_NEW By Age/Sex: 20-24 Male 2019 138
TX_NEW By Age/Sex: 20-24 Male 2019 2
TX_NEW By Age/Sex: 50+ Female 2019 62
TX_NEW By Age/Sex: 50+ Male 2019 194
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 5,622
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 144
TX_NEW People in prisons and other enclosed settings 2019 37
TX_NEW Pregnancy status 2019 1,306
TX_NEW Pregnancy status 2019 57
TX_NEW Sum of Age/Sex disaggregates 2019 1,551
TX_NEW Sum of Age/Sex disaggregates 2019 49
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 53,046
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 2,258
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 1,618
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 71
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1,622
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 69
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 29,639
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 1,239
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 20,167
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 879
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 452
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 27
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 406
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 23
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,991
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 234
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,216
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 112
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 8,213
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 396
TX_RET Numerator by Status: Breastfeeding 2019 294
TX_RET Numerator by Status: Breastfeeding 2019 6
TX_RET Numerator by Status: Pregnant 2019 2,439
TX_RET Numerator by Status: Pregnant 2019 49
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 8,644
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 416
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 474
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 27
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 419
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 24
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 5,486
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 249
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,261
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 116
TX_RET_den Denominator by Status: Breastfeeding 2019 308
TX_RET_den Denominator by Status: Breastfeeding 2019 6
TX_RET_den Denominator by Status: Pregnant 2019 2,569
TX_RET_den Denominator by Status: Pregnant 2019 52
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 55,580
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 487
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 1,390
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 10
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 1,239
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 16
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2019 240
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2019 220
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 35,457
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 17,494
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 55,532
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 484
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 484
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 55,530
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 22,230
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 194
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 5,545
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 48
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 22,103
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 197
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 5,556
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 45
Cross Cutting Budget Categories and Known Amounts Total: $288,551
Key Populations: Sex Workers $11,465
Training of health workers and community outreach workers
Key Populations: MSM and TG $3,822
Gender: Gender Based Violence (GBV) $120,020
Post GBV Care
Implementation
Monitoring and Evaluation
Food and Nutrition: Commodities $6,000
Water $33,750
Human Resources for Health $103,994
Food and Nutrition: Policy, Tools, and Service Delivery $2,000
Condoms: Policy, Tools, and Services $7,500